IVVD
Biotechnology · Healthcare
Equibles does not estimate personal net worth.
The proxy statement of Invivyd, Inc. reports total compensation of $2,029,470 for Robert Allen in fiscal 2023, including a base salary of $325,673. Disclosed compensation is on record for 2 fiscal years. Robert Allen has spoken on 1 earnings call and 2 other investor events across 1 company, most recently for Invivyd, Inc. on May 14, 2026. Invivyd, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Invivyd, Inc. includes Jeremy Gowler (CEO and COO), Marc Elia (CEO and Board Member), William Duke, Jr. (CEO) and 7 others.
“Thanks Michael and we can turn to slide 15 very quickly and as we expected we continue to see attractive neutralization data for our medicines against relevant SARS-CoV-2 variants.”
“On slide nine, I know many of you have questions about the current COVID variant landscape, including the recent sensationalized VA.3.2.2, or so-called cicada variant.”
“At InVivid, we are exploring SARS-CoV-2 spike protein structure and antibodies intensely because, thanks to our discovery platform, we do not operate within limitations imposed by human immune systems.”
Proxy statement
Start not stated–present
Last confirmed April 6, 2026
IVVD
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Invivyd, Inc. (IVVD) | Chief Scientific Officer | $325,673 | $2,029,470 |
| 2022 | Invivyd, Inc. (IVVD) | Chief Scientific Officer | — | — |